- ----------------------------------------------------------------------------
Potential Persons who are able to respond to the collection of information
contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
- -----------------------------------------------------------------------------
-----------------------
OMB APRROVAL
------------------------
OMB Number 3232-0060
------------------------
Expires: May 31, 2000
------------------------
Estimated average
burden hours
per response: 5
------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest reported): April 14, 2000
Diabetex International, Corp.
------------------------------------------------------------
(Exact Name of Registrant)
Nevada 000-30380 87-0458228
- ----------------------------- ------------------ -----------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
7321 Roseville Road,Sacramento, CA 95482
- ------------------------------------- ------------------------
(Address of principal executive office) (Zip Code)
Registrant's Telephone number, including area code (702) 293-0909
--------------------------
--------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 1. CHANGES IN CONTROL OF REGISTRANT
There are no changes in the control of the Registrant.
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
There have been no acquisitons or dispositon of assets.
ITEM 3. BANKRUPTCY OR RECERVSHIP
The Company is not in bankruptcy or recervship.
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
The Company has not changed its Certifying Accountant.
ITEM 5. RESIGNATIONS OF REGISTRANT'S DIRECTORS
While none of the Directors of the Company have resigned or failed to stand
for reelection the following changes to the Board of Directors is reported
herein:
In addition to Philip Bloomquist as Director, Benjamin Brucker
Weisman, Ph.D is added to the Board.
Mr. Bloomquist continues as the Chairman of the Board and Dr.
Weisman will assume the duties of a director and Chief Executive Officer.
ITEM 6. FINANCIAL STATEMENTS AND EXHIBITS
No financial statements are included with this report.
Included as an Exhibit is a copy of the employment contract by and between Dr.
Weisman.
ITEM 7. CHANGES IN FISCAL YEAR
There has been no change to the Company's fiscal year.
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Diabetex International, Corp.
----------------------------------
Date: April 14, 2000 /s/ Philip Bloomquist
------------------------------------
Philip Bloomquist
Secretary
EMPLOYMENT AGREEMENT
Diabetex International, Corp. (DI), the employer and Benjamin B. Weisman
(BBW), the employee enter into this contract for a twelve month period
commencing on the signing by both parties.
BBW will assume the position of chief executive officer (CEO of DI) and be
solely responsible for performing or delegating the following:
1. Hiring, dismissing and establishing the compensation package of all
employees, consultants and independent contractors. Legal counsel
and accounting firms may be changed by the Board of Directors or
shareholders at the recommendation of the CEO.
2. Establishing and supervising all strategic long term planning and
budget preparation.
3. Recommending and reviewing numbers to both the Board of Directors and
the advisory board.
4. To be the sole signatory of any corporate accounts.
5. To approve any contract which might affect the operations of DI.
6. To interact with the "Investment Community".
7. Perform those functions necessary to properly supervise and
administer the operations of the business, including the
miniturization and testing of non-invasive devices as the primary
focus , along with marketing and establishing a business model for the
metabolic activation clinics and commercializing the Hamilton-May pump.
In additon, BBW will become a member of the Board of Directors.
BBW will receive compensation of $60,000 and 132,000 shares of DI stock. The
stock may be granted through stock option or given directly to BBW or is
disignate. The determination as to the amount of payment and its form (notes
or cash) for the options, or the exercise thereof, within the terms of the
options will be made by BBW. The company's securities counsel along with
Board will review and alter, with consent of BBW, any terms deemed to be
violative applicable rules and regulations. [All shares bear (sic)
"piggy back" registration rigts. /s/PRB /s/ BBW]
BBW will, at his option assume the position of chairman of the board within a
six month period from signing this contract. Additional time and
responsibilities as chairman will be required. For this BBW will receive a
50% increase in his compensation as CEO from the time he assumes the
chairmanship.
DI warrants that it has a minimum and $350,000 in cash and no liability or
contingent liabilities exist that would reduce the $350,000 cash position
except for the current day to day operational expenses included on an ongoing
basis.
Directors and Officers liability insurance that is approved by BBW will be
obtained by DI and maintained during the term of this agreement.
Di will defend BBW from any claim arising from execution of his duties
hereunder. DI will pay any related costs not covered by insurance.
If for any reason other than malfeasant (sic) or criminal action, the contract
is terminated such as mergers or corporate combinations resulting in the
alteration of this contract BBW is to receive in full 12 months compensation
as stated in this contract.
Any disputes arising form this contract will be submitted to the New York
State Arbitration Board and their decision will be binding on both parties.
/s/ Benjamin B. Weisman 04/14/00
- ------------------------------- --------------------------
Benjamin B Weisman Date:
/s/ Philip R. Bloomquist 04/14/00
- ------------------------------- --------------------------
Diabetex International, Corp.
Philip R. Bloomquist
Board Chairman